BiologyMolecular Therapy - Oncolytics
CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
Z. Liu, X. Gao, et al.
This groundbreaking study reveals a novel CRISPR-Cas13d-based strategy with over 99% efficiency in targeting SARS-CoV-2 variants, including Delta and Omicron. Conducted by a team of experts including Zongzhi Liu, Xiang Gao, and others, this research highlights the rapid antiviral potential of this approach, paving the way for future defenses against viral threats.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
S. Sharma, T. Vercruysse, et al.
Medicine and Health
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential
B. Meyer, J. Chiaravalli, et al.
Medicine and Health
Human antibodies to SARS-CoV-2 with a recurring YYDRXG motif retain binding and neutralization to variants of concern including Omicron
H. Liu, C. I. Kaku, et al.
Medicine and Health
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
X. Zhang, H. Zhang, et al.
